Article
Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jan 2015
Togashi Yosuke, Hayashi Hidetoshi, Terashima Masato, de Velasco Marco A, Sakai Kazuko, Fujita Yoshihiko, Tomida Shuta, Nakagawa Kazuhiko, Nishio Kazuto
Abstract excerpt
INTRODUCTION: Patients with non-small-cell lung cancer (NSCLC) with somatic activating mutations of the epidermal growth factor receptor gene (EGFR mutations) generally respond to EGFR tyrosine kinase inhibitors (EGFR-TKIs). β-Catenin is a key component of the Wnt/β-Catenin signal and is an important oncogene that is involved in the pathogenesis and progression of malignant tumors, especially cancer stem cells....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.